Latanoprost/timolol, sold under the brand name Xalacom, is a combination drug used for the treatment of glaucoma, consisting of latanoprost (increase uveoscleral outflow of aqueous humor[3]) and timolol (a beta blocker decreasing the production of aqueous fluid).

Latanoprost/timolol
Combination of
LatanoprostProstaglandin
TimololBeta blocker
Clinical data
Trade namesXalacom
Routes of
administration
Eye drops
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • UK: POM (Prescription only)[2]
Identifiers
PubChem CID
KEGG
CompTox Dashboard (EPA)

Society and culture

edit

Brand names

edit

In some countries, Xalacom is marketed by Viatris after Upjohn was spun off from Pfizer.[4][5]

References

edit
  1. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  2. ^ "Summary of Product Characteristics (SmPC)". (emc). 13 June 2022. Retrieved 31 March 2024.
  3. ^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.
  4. ^ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
  5. ^ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.